Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
124 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | recruiting | Phase 4 | 100 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT07218341 | A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 4 | 150 | Eli Lilly and CompanyINDUSTRY | 17 | Sep 22, 2026 | clinicaltrials |
| Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis(STREAM-Line) |
| recruiting |
| Phase 4 |
| 330 |
| Ottawa Hospital Research InstituteOTHER |
| 1 |
| Sep 21, 2026 |
| clinicaltrials |
| NCT06908694 | Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy(GAINPCCONTROL) | active not recruiting | Phase 4 | 20 | Hamilton Health Sciences CorporationOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03975829 | Pediatric Long-Term Follow-up and Rollover Study | active not recruiting | Phase 4 | 163 | Novartis PharmaceuticalsINDUSTRY | 19 | Aug 27, 2026 | clinicaltrials |
| NCT05148494 | TES RCT Fleet Enema vs Oral Mechanical Bowel Prep(TESEO) | recruiting | Phase 4 | 66 | Nova Scotia Health AuthorityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT02386800 | CINC424A2X01B Rollover Protocol | active not recruiting | Phase 4 | 279 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 20, 2026 | clinicaltrials |
| NCT06457503 | A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer(TRANSPARENT) | recruiting | Phase 4 | 100 | Coherus Oncology, Inc.INDUSTRY | 2 | Jul 30, 2026 | clinicaltrials |
| NCT07094048 | Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager(CHUQUL_HO001) | recruiting | Phase 4 | 80 | CHU de Quebec-Universite LavalOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04549207 | Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer | active not recruiting | Phase 4 | 240 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07252726 | Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers | recruiting | Phase 4 | 50 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05754528 | Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance(REaCT-TEMPO) | active not recruiting | Phase 4 | 240 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07697287 | Oral Mucositis Management in Patients Receiving Radiation for Head and Neck Cancer: An Evaluation of a Barrier Based Treatment(TOPHAT) | active not recruiting | Phase 4 | 29 | McMaster UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05365230 | A Randomized Trial Evaluating Personalized vs Guideline-based Well Follow-up Strategies for Patients With Early-stage Breast Cancer | completed | Phase 4 | 261 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05753618 | Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy(REaCT-OGF) | recruiting | Phase 4 | 242 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT03664687 | Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)(REaCT-ZOL) | completed | Phase 4 | 211 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06183437 | The STOP-MED CTRCD Trial(STOP-MED CTRCD) | recruiting | Phase 4 | 335 | Dinesh ThavendiranathanOTHER | 6 | Jul 7, 2026 | clinicaltrials |
| NCT04877522 | Asciminib Roll-over Study | recruiting | Phase 4 | 347 | Novartis PharmaceuticalsINDUSTRY | 29 | Jul 6, 2026 | clinicaltrials |
| NCT06057402 | Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)(MagnetisMM15) | recruiting | Phase 4 | 80 | PfizerINDUSTRY | 7 | Jul 1, 2026 | clinicaltrials |
| NCT04928261 | Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy | active not recruiting | Phase 4 | 52 | Ottawa Hospital Research InstituteOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05803941 | Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | recruiting | Phase 4 | 700 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 4, 2026 | clinicaltrials |
| NCT02875314 | HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors | active not recruiting | Phase 4 | 250 | Parth PatelOTHER | 3 | Jun 3, 2026 | clinicaltrials |
| NCT04921137 | Evaluating Harms and Benefits of Endocrine Therapy in Patients ≥70 Years of Age With Lower Risk Breast Cancer | recruiting | Phase 4 | 500 | Ottawa Hospital Research InstituteOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT05864846 | A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex(EpiCom) | completed | Phase 4 | 79 | Jazz PharmaceuticalsINDUSTRY | 4 | Apr 27, 2026 | clinicaltrials |
| NCT05651282 | Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer(RESToRE) | completed | Phase 4 | 96 | University of British ColumbiaOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05203172 | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | recruiting | Phase 4 | 46 | PfizerINDUSTRY | 17 | Apr 7, 2026 | clinicaltrials |
| NCT05515354 | Smoking Cessation and Menstrual Cycle Phase(MC-NRT) | recruiting | Phase 4 | 1,200 | Centre for Addiction and Mental HealthOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06353529 | Postop Pain Management in Pituitary Tumour Patients(POPPY) | recruiting | Phase 4 | 108 | Hamilton Health Sciences CorporationOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06748001 | Avapritinib Rollover Study | recruiting | Phase 4 | 60 | Blueprint Medicines CorporationINDUSTRY | 6 | Feb 9, 2026 | clinicaltrials |
| NCT04373564 | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years(ODYSSEY) | recruiting | Phase 4 | 2,076 | GuerbetINDUSTRY | 8 | Jan 22, 2026 | clinicaltrials |
| NCT04864405 | Evaluating the Dose Timing (Morning vs Evening) of Endocrine Therapy and Its Effects on Tolerability and Compliance | completed | Phase 4 | 245 | Ottawa Hospital Research InstituteOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT02696707 | An Integrated Consent Model Study to Compare Two Standard of Care Schedules for Monitoring Cardiac Function in Patients Receiving Trastuzumab for Early Stage Breast Cancer(OTT 15-05) | completed | Phase 4 | 200 | Ottawa Hospital Research InstituteOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05222464 | Utilizing MyChart to Assess the Effectiveness of Interventions for Vasomotor Symptoms: A Feasibility Study | completed | Phase 4 | 56 | Ottawa Hospital Research InstituteOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05255003 | STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis | recruiting | Phase 4 | 50 | Tzu-Fei WangOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06251076 | Plan Development for Giving Teclistamab in the Outpatient Setting | recruiting | Phase 4 | 15 | University Health Network, TorontoOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT02688803 | Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)(OTT15-04) | terminated | Phase 4 | 2 | Ottawa Hospital Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03229200 | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | active not recruiting | Phase 4 | 297 | Pharmacyclics Switzerland GmbHINDUSTRY | 17 | Oct 30, 2025 | clinicaltrials |
| NCT01896479 | A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer(EXAMINER) | active not recruiting | Phase 4 | 247 | ExelixisINDUSTRY | 14 | Sep 2, 2025 | clinicaltrials |
| NCT04489888 | A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10) | completed | Phase 4 | 101 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Jun 19, 2025 | clinicaltrials |
| NCT02312960 | Radium-223 Dichloride Long-term Follow-up Program | completed | Phase 4 | 255 | BayerINDUSTRY | 22 | Mar 25, 2025 | clinicaltrials |
| NCT04781959 | A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy | completed | Phase 4 | 233 | Ottawa Hospital Research InstituteOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT01824537 | Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study(TRAP-HPV) | completed | Phase 4 | 372 | McGill UniversityOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT05245877 | Pre- Vs. Postoperative Thromboprophylaxis in Pancreatic Surgery(PREPOSTEROUS2) | recruiting | Phase 4 | 800 | Helsinki University Central HospitalOTHER | 3 | Feb 14, 2025 | clinicaltrials |
| NCT01943409 | Intravenous Nutrition in Hospitalized Patients: Comparison of Two Oils | completed | Phase 4 | 303 | Johane AllardOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT04078152 | Durvalumab Long-Term Safety and Efficacy Study(WAVE) | completed | Phase 4 | 163 | AstraZenecaINDUSTRY | 31 | Dec 20, 2024 | clinicaltrials |
| NCT01977651 | A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide(UPWARD) | completed | Phase 4 | 424 | Astellas Pharma Global Development, Inc.INDUSTRY | 20 | Dec 6, 2024 | clinicaltrials |
| NCT03976245 | Advanced Therapeutics in Rheumatoid Arthritis (RA) | recruiting | Phase 4 | 144 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT01794793 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | completed | Phase 4 | 337 | RECORDATI GROUPINDUSTRY | 28 | Oct 1, 2024 | clinicaltrials |
| NCT04460521 | The ACTS Trial: N-acetylcysteine (NAC) and Night-splinting as a Non-operative Treatment for Carpal Tunnel Syndrome(ACTS) | recruiting | Phase 4 | 240 | Emily KraussOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT00942968 | Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer | completed | Phase 4 | 338 | PfizerINDUSTRY | 5 | Apr 18, 2024 | clinicaltrials |
Data updated 4 days agoSource updated unknownsource: clinicaltrials